Skip to content
Clinical Trials – home

Azienda Ospedaliera Sant Anna E San Sebastiano Di Caserta

Research site

Italy Via Ferdinando Palasciano Snc, 81100 Caserta, Italy

  • 17 trials recruiting
  • Arteriosclerosis · Atrial fibrillation · Breast cancer
  • Adult patients

About Specializations

Azienda Ospedaliera Sant Anna E San Sebastiano Di Caserta in Caserta, Italy specialises in clinical trials of conditions such as Arteriosclerosis, Atrial fibrillation, Breast cancer, Acute myocardial infarction, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Diseases

At Azienda Ospedaliera Sant Anna E San Sebastiano Di Caserta, the main focus is cardiovascular research, with trials studying acute myocardial infarction, atrial fibrillation, atherosclerosis, and broader cardiovascular disease. These studies are designed to assess whether new approaches can better prevent major heart and blood vessel events, improve stroke prevention, and reduce future complications in people at high risk.

  • Testing new treatments to lower the risk of major adverse cardiovascular events
  • Evaluating therapies for stroke and systemic embolism prevention in atrial fibrillation
  • Studying options for people recovering from or at risk of acute myocardial infarction

Much of the work in this area also explores primary prevention and risk reduction in patients with elevated cardiovascular risk, including those with elevated lipoprotein(a).

Nutritional and Metabolic Diseases

The site is also active in nutritional and metabolic research, especially studies on hypertriglyceridemia and related atherosclerotic cardiovascular disease. These trials aim to understand whether targeted therapies can improve lipid levels and help lower long-term cardiovascular risk.

  • Assessing treatments for high triglycerides
  • Exploring ways to reduce cardiovascular risk linked to abnormal lipid profiles
  • Supporting prevention strategies for patients with metabolic risk factors

This research reflects a strong interest in connecting metabolic health with heart disease prevention.

Musculoskeletal Diseases

Clinical trials in musculoskeletal disease at this hospital include research on moderate to severe rotator cuff tendinopathy. The goal is to evaluate whether new treatment options can improve shoulder pain, function, and day-to-day mobility for people affected by chronic tendon injury.

  • Improving shoulder symptoms and physical function
  • Testing therapies for persistent tendon-related pain
  • Studying better care options for upper limb mobility problems

Although smaller in scope than the cardiovascular portfolio, this work broadens the site’s clinical research profile beyond heart disease.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Via Ferdinando Palasciano Snc81100 CasertaItaly
Recruiting now
17 trials
Conditions studied
32

More sites in CasertaItaly

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

46 clinical trials

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Laroprovstat
  • Sponsor:AstraZeneca AB

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Selatogrel
  • Sponsor:Viatris Innovation GmbH

Study on Long-Term Safety of Ianalumab for Patients with Systemic Lupus Erythematosus

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Study on Clazakizumab for Heart Disease in Adults with End-Stage Kidney Disease on Dialysis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Clazakizumab
  • Sponsor:CSL Behring LLC

Study on the Effectiveness of Abelacimab for High-Risk Atrial Fibrillation Patients Unsuitable for Oral Anticoagulation

Investigational
Countries:ItalyItaly
  • Participants:65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

A study of the safety and efficacy of AC01 in patients with heart failure with reduced ejection fraction

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:AnaCardio AB

Dyslipidaemia

Recruiting

Comparison of Obicetrapib and Bempedoic Acid in Patients with Dyslipidemia at High to Very High Cardiovascular Risk

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bempedoic Acid

Comparing irinotecan plus cetuximab with trifluridine and tipiracil plus bevacizumab for patients with metastatic colorectal cancer as third line treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Gruppo Oncologico Dell'Italia Meridionale

A Study Comparing PF-08046054 to Docetaxel in Adults with Previously Treated PD-L1 Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Pfizer Inc.

Study of ribociclib with or without chemotherapy for patients with hormone receptor positive, HER2 negative early breast cancer at intermediate risk

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Unicancer

Breast cancer+2

Recruiting

A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capivasertib
  • Sponsor:Relay Therapeutics Inc.

Gastric cancer+3

Recruiting

Study of HLX22, Trastuzumab, and Chemotherapy for Patients with Advanced or Metastatic Stomach and Gastroesophageal Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Shanghai Henlius Biotech Inc.
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.